表紙:吸入療法用ネブライザーの世界市場-2023年~2030年
市場調査レポート
商品コード
1316286

吸入療法用ネブライザーの世界市場-2023年~2030年

Global Inhalation Therapy Nebulizer Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
吸入療法用ネブライザーの世界市場-2023年~2030年
出版日: 2023年07月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

吸入療法用ネブライザーの世界市場は、2022年に8億米ドルに達し、2030年には16億米ドルに達することで有利な成長が予測されています。世界の吸入療法用ネブライザー市場は、予測期間中(2023-2030年)にCAGR 9.8%を示すと予測されています。

吸入療法用ネブライザー市場の動向としては、在宅医療現場でのネブライザーの使用傾向の高まり、老人人口の増加、新興市場での認知度向上と普及が挙げられます。

吸入療法用ネブライザーは、吸入によって肺に直接薬剤を送達するために使用される医療機器です。液体の薬剤を患者が容易に吸入できる細かい霧やエアロゾルに変換するように設計されています。この薬物デリバリーの方法は、喘息、慢性閉塞性肺疾患(COPD)、嚢胞性線維症などの呼吸器疾患の治療に特に効果的です。

ネブライザーは、いくつかの主要コンポーネントから構成されています。主な構成要素はネブライザー室であり、液体薬剤を保持します。チャンバーは、ネブライザーのタイプに応じて、エアコンプレッサーまたは超音波トランスデューサに接続されています。コンプレッサーまたはトランスデューサーは、それぞれ高速の空気流または超音波振動を発生させ、液体薬剤を撹拌し、微小な液滴または粒子に分解します。

さらに、呼吸器疾患の有病率の増加、ネブライザー技術の進歩による効率性、使いやすさ、携帯性の向上、多くの国の政府や医療機関が呼吸器ケアの改善に注力し、ヘルスケアインフラに投資していることなどが、予測期間中に市場を牽引すると予想される要因です。

市場力学

市場参入企業別製品上市の増加が吸入療法用ネブライザーの世界市場成長を牽引すると予測

2023年4月、ヘルスケアとウェルネスで有名なQMS MAS社は、Q Devicesとして知られるポイントオブケア機器の広範な製品ラインを提供することで、消費者への直接販売を開始しました。また、インドの有名なデジタルテクノロジー企業であるVaranium Cloud Ltd.と共同で、Vyanaと名付けられた革新的な医療用ウェアラブルを発売しました。Vyanaは、バイタルサインを継続的に監視し、重篤な変動が発生した場合にユーザーと緊急連絡先に迅速なメッセージを伝えることで、医療用ウェアラブル市場の空白を埋めることを目的としています。このガジェットはリスクの高い人々を対象としており、幅広く利用される可能性が高いです。

これらのライフスタイル・モニタリング・ガジェットは、最高の品質要件を上回っており、消費者に健康的なライフスタイルを奨励するという同社の目的に沿ったものです。これらの機器は、店頭でも、Amazonや同社のウェブサイトQDevices.lifeなどのプラットフォームを通じてオンラインでも入手可能です。このように、上記の要因から、予測期間中、同市場は牽引役となることが期待されます。

ネブライザーによる薬物送達におけるさまざまな振動式陽圧呼吸(OPEP)デバイスの評価が、世界の吸入療法用ネブライザー市場の成長を促進する見込み

2022年8月15日に発表されたTrudell Medical UK Limitedの記事によると、気管支拡張症やCOPDの治療のために、異なるOPEPデバイスがネブライズされた薬をどの程度送達するかを調査しました。これまでの組み合わせと比較すると、エアロビカOPEP装置とエアロエクリプスII BANネブライザーは、3倍以上の量の薬剤を送達し、はるかに優れた結果をもたらしました。

この調査結果は、薬物送達を最適化するために適切なOPEP装置とネブライザーの組み合わせを選択することの重要性を強調しています。OPEPとネブライザーを組み合わせた治療は、患者の効率、利便性、アドヒアランスの点で利点があるが、適切な薬物送達を確保するために注意を払わなければならないです。したがって、上記の要因により、市場は予測期間中に拡大すると予想されます。

吸入療法におけるコンプライアンスとアドヒアランスの向上における限界が、世界の吸入療法用ネブライザー市場の成長を妨げると予想される

コンプライアンスとアドヒアランスは、吸入治療の有効性にとって極めて重要です。しかし、患者は、物忘れ、不快感、アドヒアランスの必要性の理解不足など、様々な理由で推奨される吸入レジメンを守ることが困難な場合があります。

物忘れは多くの患者にとって典型的な問題です。多忙なスケジュールや様々な業務に追われていると、吸入を怠ったりサボったりしがちです。処方された薬を指示通りに飲まないと、治療が不十分になり、治療効果が低下し、おそらく症状管理が不十分になる可能性があります。

不便さもコンプライアンスを妨げる要因の一つです。吸入デバイスの中には、特定の準備段階や人目につかない環境での投与が必要で、面倒で時間がかかると感じられるものもあります。このプロセスを不便に感じたり、日常生活に支障をきたしたりする患者は、吸入セッションをスキップしたり遅らせたりする傾向が強くなり、治療成績が損なわれる可能性があります。したがって、上記の要因のために、予測期間中、市場は低迷すると予想されます。

COVID-19の影響分析

COVID-19が吸入療法用ネブライザー市場に与える影響は大きいです。COVID-19に伴う呼吸器合併症は吸入療法用ネブライザーの需要急増を生み出しました。これらのデバイスは肺に直接薬剤を供給するために一般的に使用され、COVID-19患者の呼吸器症状を管理するために極めて重要です。ネブライザーに対する需要の高まりは、市場の成長拡大につながっています。

パンデミックの間、社会的距離の縮小策と対面でのヘルスケア受診を最小限に抑える必要性から、遠隔医療と遠隔患者モニタリングが注目されました。この変化はネブライザー装置の利用に影響を与え、一部の患者は遠隔で管理できる代替治療法を選択しました。その結果、患者の行動におけるこの変化は、ネブライザー市場の成長に若干の悪影響を及ぼしました。

パンデミック(世界的大流行)時には感染予防・管理対策が極めて重要になり、機器の洗浄・消毒プロトコルが重視されるようになっています。このような衛生面の重視と、使い捨てまたは簡単に洗浄できるネブライザー部品の必要性が市場に影響を及ぼし、感染リスクを軽減できる装置が好まれるようになっています。

そのため、COVID-19によって吸入療法用ネブライザーの需要が増加する一方で、サプライチェーンの混乱やヘルスケア提供方法の変化が市場の成長にとって課題となっています。しかし、COVID-19のシナリオでもCOVID-19以外のシナリオでも呼吸器ケアの重要性は依然として大きいため、市場への長期的な影響はプラスに働くと予想されます。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争は、医療業界を含むさまざまなセクターにいくつかの影響を与えています。紛争はネブライザーを含む医療機器のサプライチェーンの混乱につながる可能性があります。ウクライナは製造能力が高いことで知られており、紛争が生産施設や輸送ルートに影響を及ぼせば、市場でネブライザーが不足する可能性があります。

紛争や情勢不安の時期には、避難、ストレス、劣悪な生活環境、環境汚染物質への暴露など、さまざまな要因によって呼吸器疾患が増加することが多いです。このような呼吸器治療に対する需要の増加は、吸入療法の選択肢としてのネブライザーに対するニーズの急増につながる可能性があります。

戦争は被災地のヘルスケア・インフラに負担をかけ、ネブライザーを含む医療用品の不足につながるかもしれないです。リソースの重点が緊急ニーズへの対応に移り、ネブライザーの入手や流通に影響が出る可能性があります。

紛争中に課された国際的な制裁措置や貿易制限は、医療機器の輸出入に影響を与える可能性があります。このことは、ウクライナとロシアの両国だけでなく、紛争に関与している他の国々におけるネブライザーの入手可能性に影響を与える可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • ホームケア用ネブライザーのディスカウントに関する市場参入企業の契約締結
      • 喘息用吸入療法ネブライザーにおける臨床試験の増加
    • 抑制要因
      • 超音波ネブライザーの欠点
    • 機会
      • 可能性の高い個別化吸入AATの入手可能性の増加
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 タイプ別

  • メッシュネブライザー
  • 空気圧式ネブライザー
  • 超音波ネブライザー
  • ジェットネブライザー

第9章 用途別

  • 喘息
  • 慢性閉塞性肺疾患
  • 嚢胞性線維症
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第13章 企業プロファイル

  • Rossmax International Ltd
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Boehringer Ingelheim GmbH
  • OMRON Corporation
  • Koninklijke Philips N.V.
  • PARI Pharma
  • BD
  • Medline Industries, Inc.
  • Briggs Healthcare
  • GF Health Products, Inc.
  • Drive DeVilbiss International

第14章 付録

目次
Product Code: MD2898

Market Overview

The global inhalation therapy nebulizer market reached US$ 0.8 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.6 billion by 2030. The global inhalation therapy nebulizer market is expected to exhibit a CAGR of 9.8% during the forecast period (2023-2030).

There is a growing trend of using nebulizers in homecare settings, increasing the geriatric population, and growing awareness and adoption in emerging markets are some of the trends for the inhalation therapy nebulizer market.

The inhalation therapy nebulizer is a medical device used for delivering medication directly to the lungs through inhalation. It is designed to convert liquid medication into a fine mist or aerosol that can be easily inhaled by the patient. This method of drug delivery is particularly effective for treating respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

The nebulizer consists of several key components. The primary component is the nebulizer chamber, which holds the liquid medication. The chamber is connected to an air compressor or ultrasonic transducer, depending on the type of nebulizer. The compressor or transducer generates a high-velocity flow of air or ultrasonic vibrations, respectively, which agitate the liquid medication, breaking it down into tiny droplets or particles.

Furthermore, the increasing prevalence of respiratory diseases, and advances in nebulizer technology have improved their efficiency, ease of use, and portability, and governments and healthcare organizations in many countries are focusing on improving respiratory care and investing in healthcare infrastructure are the factors expected to drive the market over the forecast period.

Market Dynamics

The Increasing Product Launches by the Market Players are Expected to Drive Global Inhalation Therapy Nebulizer Market Growth

On April 2023, QMS MAS, a well-known healthcare and wellness firm, made its direct-to-consumer debut by offering an extensive line of point-of-care devices known as Q Devices. In conjunction with Varanium Cloud Ltd., a renowned digital technology business in India, the company also launched an innovative medical wearable named Vyana. Vyana is intended to fill a void in the medical wearable market by continually monitoring vital signs and giving fast messages to the user and their emergency contacts in the event of severe variations. The gadget is intended for high-risk populations and is likely to be extensively utilized.

These lifestyle monitoring gadgets exceed the highest quality requirements and are in line with the company's objective of encouraging a healthy lifestyle among consumers. The devices are accessible both in shops and online through platforms such as Amazon and the company's website, QDevices.life. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Evaluation of Different Oscillating Positive Expiratory Pressure (OPEP) Devices in Delivering Nebulized Medications is Expected to Drive Global Inhalation Therapy Nebulizer Market Growth

According to Trudell Medical UK Limited Article, published on August 15, 2022, the research looked at how well different OPEP devices delivered nebulized medicine for the treatment of bronchiectasis and COPD. When compared to previous combinations, the AEROBIKA OPEP device and AEROECLIPSE II BAN Nebulizer produced much better outcomes, delivering more than three times the quantity of medicine.

The findings highlight the significance of selecting the right OPEP device and nebulizer combination to optimize medication delivery. Combining OPEP and nebulizer treatment has advantages in terms of patient efficiency, convenience, and adherence, but care must be taken to ensure proper medication delivery. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Limitations in Enhancing Compliance and Adherence in Inhalation Therapy are Expected to Hamper the Global Inhalation Therapy Nebulizer Market Growth

Compliance and adherence are critical to the efficacy of inhalation treatment. However, patients may have difficulty following their recommended inhalation regimens for a variety of reasons, including forgetfulness, discomfort, and a lack of understanding of the need for adherence.

Forgetfulness is a typical problem for many patients. With hectic schedules and various duties, it's easy to neglect or skip inhalation sessions. Failure to take the prescribed medicine as directed can result in insufficient treatment, lowering the effectiveness of the therapy and perhaps leading to inadequate symptom management.

Inconvenience is another factor that can hinder compliance. Some inhalation devices may be perceived as cumbersome or time-consuming, requiring specific preparation steps or a secluded environment for administration. Patients who find the process inconvenient or disruptive to their daily routines may be more inclined to skip or delay their inhalation sessions, compromising the therapeutic outcomes. Thus, owing to the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The impact of COVID-19 on the inhalation therapy nebulizer market has been significant. The respiratory complications associated with COVID-19 created a surge in demand for inhalation therapy nebulizers. These devices are commonly used to deliver medication directly to the lungs, making them crucial for managing respiratory symptoms in COVID-19 patients. The heightened demand for nebulizers resulted in increased market growth.

Due to social distancing measures and the need to minimize in-person healthcare visits, telemedicine, and remote patient monitoring gained prominence during the pandemic. This shift impacted the utilization of nebulizer devices, as some patients opted for alternative treatment options that could be managed remotely. Consequently, this change in patient behavior had a slight negative impact on the growth of the nebulizer market.

Infection prevention and control measures became crucial during the pandemic, leading to a greater emphasis on device cleaning and disinfection protocols. This focus on hygiene and the need for disposable or easily cleanable nebulizer components influenced the market, with a preference for devices that could mitigate infection risks.

Therefore, while the demand for inhalation therapy nebulizers increased due to COVID-19, supply chain disruptions and changes in healthcare delivery methods posed challenges to the market's growth. However, the long-term impact on the market is expected to be positive as the importance of respiratory care remains significant in both COVID-19 and non-COVID-19 scenarios.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine war has had several impacts on various sectors, including the medical industry. The conflict may lead to disruptions in the supply chains of medical devices, including nebulizers. Ukraine is known for its manufacturing capabilities, and if the conflict affects production facilities or transportation routes, it could result in a shortage of nebulizers in the market.

During times of conflict and unrest, there is often an increase in respiratory illnesses due to various factors such as displacement, stress, poor living conditions, and exposure to environmental pollutants. This increased demand for respiratory treatments may lead to a surge in the need for nebulizers as an inhalation therapy option.

The war may place a strain on the healthcare infrastructure in affected areas, leading to a shortage of medical supplies, including nebulizers. The focus of resources might shift towards addressing immediate emergency needs, potentially impacting the availability and distribution of nebulizers.

International sanctions and trade restrictions imposed during the conflict could impact the import and export of medical devices. This could affect the availability of nebulizers in both Ukraine and Russia, as well as other countries involved in the conflict.

Segment Analysis

The global inhalation therapy nebulizer market is segmented based on type, application, distribution channel, and region.

COPD from the Application Segment Account for 28.2% of the Market Share Owing to the Increasing Prevalence of COPD, Patient Convenience and Ease of Use, and Advancements in Nebulizer Technology

According to Global Initiative for Chronic Obstructive Lung Disease Report 2022, an estimated 200 million people have COPD, of which about 3.2 million die each year, making it the third-leading cause of death worldwide.

Cigarette smoking is a major environmental risk factor for COPD, leading to respiratory symptoms, lung function abnormalities, and increased mortality rates. However, it's worth noting that not all heavy smokers develop COPD. Passive exposure to different types of tobacco smoke and marijuana also poses a risk. Smoking during pregnancy can affect lung development in the fetus and potentially lead to abnormal immune responses in the future.

In low- and middle-income countries (LMICs), nonsmokers account for a significant portion of COPD cases, potentially up to 60-70%. Household air pollution caused by burning biomass fuels like wood, animal dung, crop residues, and coal in poorly functioning stoves is a common risk factor in LMICs. This household air pollution contributes to over 50% of the global burden of COPD.

COPD in nonsmokers, compared to smokers, is more prevalent among females, and younger individuals, and exhibits similar or milder respiratory symptoms and quality of life impairment. They show different patterns of lung function decline, with more small airway obstruction but less emphysema.

Occupational exposures, such as exposure to organic and inorganic dusts, chemicals, and fumes, are an under-recognized risk factor for COPD. Workplace exposures contribute to a significant fraction of COPD cases, particularly among never-smokers.

Air pollution, including particulate matter, ozone, nitrogen or sulfur oxides, heavy metals, and other pollutants, is a major global cause of COPD. It accounts for approximately 50% of the attributable risk for COPD in LMICs. Chronic exposure to air pollution impairs lung growth in children, accelerates lung function decline in adults, and increases the risk of COPD, especially when combined with other risk factors.

Air pollution also exacerbates COPD symptoms, leading to more frequent exacerbations, hospitalizations, and increased mortality rates. Therefore, there is an increase in demand for inhalation therapy nebulizers. Thus, owing to the above factors, the market segment accounted to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share Owing to the Increasing Prevalence of Asthma Cases, Rising Geriatric Population, Well Healthcare Expenditure, and Product launches by the Key Players

The increasing prevalence of asthma cases, technological advancement in nebulizer devices, well-established infrastructure, rising geriatric population, product launches, approval, and acquisitions by the market players are some factors due to which the market is expected to boost in the forecast period.

For instance, according to the Asthma and Allergy Foundation of America Report 2022, approximately 26 million individuals in the United States have asthma, which is equivalent to about 1 out of every 13 people. Out of this total, around 21 million are adults aged 18 and older. Asthma rates are highest among Black adults in the country.

Moreover, asthma is more prevalent in female adults compared to male adults, with approximately 9.7% of women and 6.2% of men being affected. Among children, asthma is a prominent chronic disease, affecting approximately 4.8 million children under the age of 18. Non-Hispanic Black children are over twice as likely to have asthma as non-Hispanic white children. Additionally, asthma is more common among male children than female children, with approximately 7.3% of boys and 5.6% of girls being affected.

Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Rossmax International Ltd, Boehringer Ingelheim GmbH, OMRON Corporation, Koninklijke Philips N.V., PARI Pharma, BD, Medline Industries, Inc., Briggs Healthcare, GF Health Products, Inc., and Vectura Group plc among others.

Why Purchase the Report?

  • To visualize the global inhalation therapy nebulizer market segmentation based on the type, application, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of inhalation therapy nebulizer market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global inhalation therapy nebulizer market report would provide approximately 61 tables, 59 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Market Players Signing Agreements for Discounted Home Care Nebulizers
      • 4.1.1.2. Increasing Clinical Trials in Inhalation Therapy Nebulizer for Asthma
    • 4.1.2. Restraints
      • 4.1.2.1. Disadvantages of Ultrasonic Nebulizers
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing Availability of High Potential Personalized Inhaled AAT
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Mesh Nebulizer*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Pneumatic Nebulizer
  • 8.4. Ultrasonic Nebulizer
  • 8.5. Jet nebulizers

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Asthma*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. COPD
  • 9.4. Cystic Fibrosis
  • 9.5. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. U.K.
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. Rossmax International Ltd*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Boehringer Ingelheim GmbH
  • 13.3. OMRON Corporation
  • 13.4. Koninklijke Philips N.V.
  • 13.5. PARI Pharma
  • 13.6. BD
  • 13.7. Medline Industries, Inc.
  • 13.8. Briggs Healthcare
  • 13.9. GF Health Products, Inc.
  • 13.10. Drive DeVilbiss International

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us